BioCentury | Apr 16, 2021
Targets & Mechanisms

New targets featured at AACR signal growing opportunity in established mechanisms

The bulk of the new targets presented at AACR21 involve pathways and mechanisms active in tumor cells rather than immune cells, reflecting the biotech industry’s growing interest in targeted oncology and...
BioCentury | Dec 31, 2020
Distillery Therapeutics

SIRT5 overexpression could rescue mitochondrial disease induced by SUCLA2 mutations

...hypersuccinylated proteins; 102 of the proteins were hypersuccinylated in SIRT5 mouse embryonic fibroblasts. Overexpression of SIRT5...
...with systemic SUCLA2 knockout partially reversed protein succinylation and improved survival.TARGET/MARKER/PATHWAY: Succinate-CoA ligase ADP-forming β subunit (SUCLA2); sirtuin 5 (SIRT5)EXPERIMENTAL...
...California San Francisco University of Helsinki Buck Institute for Research on Aging Succinate-CoA ligase ADP-forming beta subunit (SUCLA2) Sirtuin 5 (SIRT5) Endocrine/Metabolic Mitochondrial...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Liver cancer In silico , in vitro , cell culture and mouse studies identified a positive allosteric modulator (PAM) of SIRT6 that could help treat hepatocellular carcinoma (HCC). In silico screening of a small molecule library...
BioCentury | Aug 17, 2018
Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
BioCentury | Aug 14, 2018
Company News

Juvenescence, partners form anti-aging biotech

Juvenescence Ltd. (Douglas, Isle of Man), Insilico Medicine Inc. (Baltimore, Md.) and the Buck Institute for Research on Aging (Novato, Calif.) partnered to form anti-aging company Napa Therapeutics Ltd. (Tortola, British Virgin Islands). Napa will...
BioCentury | Apr 17, 2018
Distillery Therapeutics

Neurology

INDICATION: Neurology Cell culture and mouse studies suggest promoting the expression of SIRT1 could help treat Alzheimer’s disease and other neurodegenerative tauopathies. In HEK cells expressing mutant human tau, plasma vector-encoded SIRT1 decreased levels of...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...INDICATION: Bone cancer; colorectal cancer Cell culture and mouse studies suggest inhibiting SIRT5-mediated desuccinylation of SHMT2...
...SHMT2 desuccinylation in osteosarcoma and colorectal cancer models. TARGET/MARKER/PATHWAY: Serine hydroxymethyltransferase 2 mitochondrial (SHMT2); sirtuin 5 (SIRT5...
...CONTACT: Jianyuan Luo, Peking University, Beijing, China email: luojianyuan@bjmu.edu.cn Winnie Pong Peking University Serine hydroxymethyltransferase 2 mitochondrial (SHMT2) Sirtuin 5 (SIRT5...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
BioCentury | Nov 14, 2017
Preclinical News

Hybrid T cells show anticancer effects

A study published in Cell Metabolism by researchers at Medical University of South Carolina and colleagues showed that the enhanced antitumor effect of a hybrid of T helper types 1 (Th1) and 17 (Th17) cells...
BioCentury | Oct 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest activating SIRT7 or promoting its expression could help treat metastatic breast cancer. In samples from metastatic breast cancer patients, levels of SIRT7 were lower...
Items per page:
1 - 10 of 163